TABLE A3.
Rates of veno-occlusive disease for the studies of the two regimens of Mylotarg
| (a) 6 mg/m2 | ||
|---|---|---|
| Events | Total | |
| Study 101 | 1 | 8 |
| Study 102 | 6 | 14 |
| Study 103 | 0 | 6 |
| Study 100374 | 2 | 6 |
| Thomas, 2005 | 1 | 6 |
| Piccaluga, 2004 | 0 | 7 |
| Zwaan, 2003 | 0 | 1 |
| (b) 3 mg/m2 | ||
| Events | Total | |
| MyloFrance 1 | 0 | 57 |
| Thomas, 2005 | 0 | 24 |
| Brethon, 2006 | 0 | 6 |